MX2022015788A - Metodos y composiciones para editar el sitio de b2m en celulas b. - Google Patents
Metodos y composiciones para editar el sitio de b2m en celulas b.Info
- Publication number
- MX2022015788A MX2022015788A MX2022015788A MX2022015788A MX2022015788A MX 2022015788 A MX2022015788 A MX 2022015788A MX 2022015788 A MX2022015788 A MX 2022015788A MX 2022015788 A MX2022015788 A MX 2022015788A MX 2022015788 A MX2022015788 A MX 2022015788A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- modified
- methods
- killing
- gene
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 5
- 230000000735 allogeneic effect Effects 0.000 abstract 3
- 210000002865 immune cell Anatomy 0.000 abstract 3
- 101150076800 B2M gene Proteins 0.000 abstract 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 abstract 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/13—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/35—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Document Processing Apparatus (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047978P | 2020-07-03 | 2020-07-03 | |
| US202063114131P | 2020-11-16 | 2020-11-16 | |
| PCT/US2021/039953 WO2022006309A1 (en) | 2020-07-03 | 2021-06-30 | Methods and compositions for editing the b2m locus in b cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015788A true MX2022015788A (es) | 2023-02-27 |
Family
ID=79315579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015788A MX2022015788A (es) | 2020-07-03 | 2021-06-30 | Metodos y composiciones para editar el sitio de b2m en celulas b. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4175651A4 (https=) |
| JP (1) | JP2023532917A (https=) |
| KR (1) | KR20230035048A (https=) |
| CN (1) | CN116033910A (https=) |
| AU (1) | AU2021300358A1 (https=) |
| BR (1) | BR112022026534A2 (https=) |
| CA (1) | CA3186620A1 (https=) |
| IL (1) | IL299491A (https=) |
| MX (1) | MX2022015788A (https=) |
| WO (1) | WO2022006309A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250222138A1 (en) * | 2022-03-28 | 2025-07-10 | Ramot At Tel-Aviv University Ltd. | Site-specific in vivo t cell engineering, systems, compositions and methods thereof |
| CA3261942A1 (en) * | 2022-08-01 | 2024-02-08 | Idexx Laboratories, Inc. | FRACTIONAL ABUNDANCE DOSES OF HUMAN MOUSE |
| EP4698226A2 (en) * | 2023-04-17 | 2026-02-25 | Be Biopharma, Inc. | Engineered cell preparations for treatment of hemophilia |
| CN120866304A (zh) * | 2024-04-23 | 2025-10-31 | 南京奇迹生物科技有限公司 | 对b2m基因座的基因编辑方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073955A2 (en) * | 2014-11-06 | 2016-05-12 | President And Fellows Of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| IL297018A (en) * | 2015-12-18 | 2022-12-01 | Sangamo Therapeutics Inc | Directed cleavage of cell mhc receptor |
| US12144825B2 (en) * | 2017-06-30 | 2024-11-19 | Cellectis | Cellular immunotherapy for repetitive administration |
| US20200407713A1 (en) * | 2017-11-16 | 2020-12-31 | Mogam Institute For Biomedical Research | Transformed human cell and use thereof |
| US12378572B2 (en) * | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| CA3122131A1 (en) * | 2018-09-21 | 2020-03-26 | Zonghai Li | Method for gene editing of cell on the basis of crispr/cas system |
| UY38427A (es) * | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
-
2021
- 2021-06-30 MX MX2022015788A patent/MX2022015788A/es unknown
- 2021-06-30 WO PCT/US2021/039953 patent/WO2022006309A1/en not_active Ceased
- 2021-06-30 AU AU2021300358A patent/AU2021300358A1/en active Pending
- 2021-06-30 EP EP21832140.4A patent/EP4175651A4/en active Pending
- 2021-06-30 IL IL299491A patent/IL299491A/en unknown
- 2021-06-30 CA CA3186620A patent/CA3186620A1/en active Pending
- 2021-06-30 JP JP2022581341A patent/JP2023532917A/ja active Pending
- 2021-06-30 BR BR112022026534A patent/BR112022026534A2/pt unknown
- 2021-06-30 CN CN202180047549.4A patent/CN116033910A/zh active Pending
- 2021-06-30 KR KR1020237001885A patent/KR20230035048A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230035048A (ko) | 2023-03-10 |
| JP2023532917A (ja) | 2023-08-01 |
| CA3186620A1 (en) | 2022-01-06 |
| EP4175651A1 (en) | 2023-05-10 |
| WO2022006309A1 (en) | 2022-01-06 |
| CN116033910A (zh) | 2023-04-28 |
| AU2021300358A1 (en) | 2023-02-02 |
| EP4175651A4 (en) | 2024-08-14 |
| IL299491A (en) | 2023-02-01 |
| BR112022026534A2 (pt) | 2023-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015788A (es) | Metodos y composiciones para editar el sitio de b2m en celulas b. | |
| AR069883A1 (es) | Virus de la estomatitis vesicular geneticamente modificado, composicion inmunogenica que lo comprende, metodo para producirlo, metodos para adaptar un virus para crecer en el cultivo de cedula y para proteger un mamifero contra la infeccion con un organismo patogeno | |
| EP4512823A3 (en) | Process for generating therapeutic compositions of engineered cells | |
| CO2021005289A2 (es) | Métodos y composiciones para terapia con células oculares | |
| MY180750A (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy | |
| BR112016023523A2 (pt) | produtos de células t modificados em gene de composição definida | |
| BR112017007770A2 (pt) | cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc. | |
| MX2022003039A (es) | Metodo de seleccion de donantes universales para identificar donantes de celulas nk. | |
| MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
| BR112023018844A2 (pt) | Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas | |
| CL2023003086A1 (es) | Composiciones y métodos para reducir los hla-a en una célula | |
| BR112021023029A2 (pt) | Células, tecidos, órgãos e/ou animais tendo um ou mais de genes modificados para sobrevivência e/ou tolerância de xenoenxerto potencializada(s) | |
| MX2019014578A (es) | Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal. | |
| BR112023015097A2 (pt) | Proteínas de ligação a psma e usos das mesmas | |
| WO2021101273A3 (ko) | 조절 t 세포 배양용 조성물 및 이의 용도 | |
| AR087980A1 (es) | Actividad de dnasa endogena para reducir el contenido de adn | |
| MX2023008162A (es) | Composiciones y metodos para la expansion de celulas t y linfocitos infiltrantes del tumor. | |
| MX388475B (es) | Selección de células pluripotentes para producir ratones hembra xy fértiles. | |
| BR112021023554A2 (pt) | Composições e métodos para cultura de células vegetais | |
| MX2023008055A (es) | Métodos para inducir tolerancia inmune con anticuerpos anti-cd154 modificados. | |
| MX2023005492A (es) | Métodos de cultivo de células inmunitarias. | |
| MX2024015534A (es) | Composiciones y metodos para reducir mhc de clase i en una celula | |
| EP4234686A3 (en) | Transduction and expansion of cells | |
| AR069884A1 (es) | Metodos para empacar vectores de virus de estomatitis vesicular de propagacion defectuosa | |
| BR112021021349A2 (pt) | Métodos de fabricação de células car t alogênicas |